Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | HRAS G13R |
Gene Variant Detail | |
Relevant Treatment Approaches | MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor PI3K Inhibitor (Pan) PIK3CA inhibitor PIK3CB inhibitor PIK3CD inhibitor PIK3CG inhibitor RAS Inhibitor (Pan) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK F1245Y HRAS G13R | neuroblastoma | predicted - resistant | Lorlatinib | Case Reports/Case Series | Actionable | In a Phase I trial, a neuroblastoma patient harboring ALK F1245Y developed progressive disease on treatment with Lorbrena (lorlatinib) and was found to have acquired HRAS G13R via circulating tumor DNA (PMID: 37147298; NCT03107988). | 37147298 |
BRAF G466E HRAS G13R | Advanced Solid Tumor | sensitive | Tipifarnib | Preclinical - Cell culture | Actionable | In a preclinical study, HRAS-null, NRAS-null, and KRAS knockout cells expressing HRAS G13R and BRAF G466E were sensitive to Zarnestra (tipifarnib) in culture, demonstrating decreased cell viability (PMID: 39152269). | 39152269 |
BRAF G466E HRAS G13R | Advanced Solid Tumor | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, HRAS-null, NRAS-null, and KRAS knockout cells expressing HRAS G13R and BRAF G466E were sensitive to Mekinist (trametinib) in culture, demonstrating decreased cell viability (PMID: 39152269). | 39152269 |
BRAF G466E HRAS G13R | Advanced Solid Tumor | sensitive | Tipifarnib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, combination treatment with Zarnestra (tipifarnib) and Mekinist (trametinib) resulted in decreased viability of HRAS-null, NRAS-null, and KRAS knockout cells expressing HRAS G13R and BRAF G466E in culture (PMID: 39152269). | 39152269 |
HRAS G13R PTEN loss | Advanced Solid Tumor | resistant | AZD8186 | Preclinical - Cell culture | Actionable | In a preclinical study, HRAS-null, NRAS-null, and KRAS knockout cells with PTEN loss and expressing HRAS G13R were not sensitive to treatment with AZD8186 in culture (PMID: 39152269). | 39152269 |
HRAS G13R PTEN loss | Advanced Solid Tumor | resistant | Pictilisib | Preclinical - Cell culture | Actionable | In a preclinical study, HRAS-null, NRAS-null, and KRAS knockout cells with PTEN loss and expressing HRAS G13R were not sensitive to treatment with Pictilisib (GDC-0941) in culture (PMID: 39152269). | 39152269 |
HRAS G13R PIK3CA H1047R | Advanced Solid Tumor | resistant | Tipifarnib | Preclinical - Cell culture | Actionable | In a preclinical study, HRAS-null, NRAS-null, and KRAS knockout cells expressing HRAS G13R and PIK3CA H1047R were resistant to Zarnestra (tipifarnib) in culture (PMID: 39152269). | 39152269 |
HRAS G13R PIK3CA H1047R | Advanced Solid Tumor | resistant | Alpelisib | Preclinical - Cell culture | Actionable | In a preclinical study, HRAS-null, NRAS-null, and KRAS knockout cells expressing HRAS G13R and PIK3CA H1047R were resistant to Piqray (alpelisib) in culture (PMID: 39152269). | 39152269 |
HRAS G13R PIK3CA H1047R | Advanced Solid Tumor | resistant | Pictilisib | Preclinical - Cell culture | Actionable | In a preclinical study, HRAS-null, NRAS-null, and KRAS knockout cells expressing HRAS G13R and PIK3CA H1047R were resistant to Pictilisib (GDC-0941) in culture (PMID: 39152269). | 39152269 |